Primary small cell oesophageal carcinoma: A retrospective study of different ‎treatment modalities

Table 1 Demographics of the patients and the tumours

Characteristic	All patients (28)	Palliative chemotherapy (15)	Concurrent chemoradiotherapy (5)	Sequential chemoradiotherapy (8)
Age (yr)
Median	72	72	79	70
Range	52-86	53-86	58-83	52-78
Performance status of 0 or 1 (%)	82	67	100	100
Sex
Male (%)	57	53	100	38
Female (%)	43	47	None	62
Tumour Stage
Limited (%)	60	27	100	100
Extensive (%)	40	73	None	None
Location of the tumour
Mid-oesophagus (%)	18	27	None	13
Low-oesophagus (%)	82	73	100	87

Table 2 Clinical and treatment details of the 15 patients who received palliative chemotherapy

Patient	Age	Sex	PS	Stage	Site	CT	Cycles (n)	Palliative RT	Response	Survival (mo)
1	80	M	1	ES	Low	PE	6	No	PR	16
2	58	M	1	ES	Low	PE	6	No	PR	12
3	67	F	2	ES	Mid	P	4	No	PR	9
4	80	M	3	ES	Mid	P	2	No	UK	1.5
5	59	M	1	ES	Mid	PE	2	Yes	UK	2
6	70	F	1	ES	Low	PE	4	Yes	PR	12
7	53	F	0	ES	Low	CE	6	No	PR	10
8	62	F	2	ES	Mid	P	4	No	PR	7
9	65	M	0	ES	Low	PE	4	No	PR	3.5
10	81	F	3	ES	Low	None	0	No	NA	1
11	84	F	2	ES	Low	None	0	Yes	NA	1
12	86	M	1	LS	Low	P	2	Yes	SD	14
13	75	M	1	LS	Low	PE	4	No	PR	3
14	72	M	0	LS	Low1	ECX/CE	3/3	No	SD	13
15	75	F	1	LS	Low	PE	2	No	PR	5.5

¹Mixed pathology of small cell oesophageal cancer and squamous cell carcinoma. CE: Cisplatin and etoposide; CT: Chemotherapy; ED: Extensive stage; ECX: Epirubicin, cisplatin and capecitabine; F: Female; LD: Limited disease; M: Male; Mid: Middle; NA: Not applicable; Low: Lower; PE: Carboplatin and etoposide; PS: Performance status; PR: Partial response; RT: Radiotherapy; SD: Stable disease; UK: Unknown.

Table 3 Clinical and treatment details of the five patients who received concurrent chemoradiotherapy

Patient	Age	Sex	PS	Site	CT	Cycles (n)	RT dose	Response	Relapse	Alive1	Survival (mo)
1	83	M	0	Low	PE	4	50 Gy in 25 Fr	PR	Local	1	45
2	79	M	1	Low2	CE	4	45 Gy in 25 Fr	CR	Liver	1	38
3	73	M	1	Low	PE	3	45 Gy in 25 Fr	CR	None	0	92
4	58	M	1	Low	CE	4	50 Gy in 25 Fr	CR	Local3	0	110
5	79	M	0	Low	CE	4	45 Gy in 25 Fr	PR	Liver	1	40

¹1 = Died, 0 = Otherwise.

²Mixed pathology initially, biopsy confirmed recurrence of squamous cell carcinoma only.

³New primary with adenocarcinoma; patient had salvage surgery. CE: Cisplatin and etoposide; CT: Chemotherapy; Fr: Fractions; M: Male; PE: Carboplatin and etoposide; PS: Performance status; PR: Partial response; RT: Radiotherapy.

Table 4 Clinical and treatment details of the 8 patients who received sequential chemoradiotherapy

Patient	Age	Sex	PS	Site	CT	Cycles (n)	RT dose	Response	Site ofrelapse	2nd Line CT	Survival(mo)
1	52	F	0	Mid	CE	6	50 Gy in 20 Fr	CR	Liver	2 Top	25
2	78	F	0	Low	PE	1	50 Gy in 20 Fr	CR	UK	None	25
3	71	M	0	Low	CE/PE	3	50 Gy in 20 Fr	CR	Local	6 PE	23
4	70	M	1	Low1	PE	5	50 Gy in 20 Fr	PR	Local	2 PE	20
5	67	F	1	Low	CE	4	45 Gy in 25 Fr	PR	Local2	3 ECX	65.5
6	70	F	1	Low	CE	4	50 Gy in 20 Fr	UK	UK	None	19
7	73	F	1	Low	PE	4	4005 cGy in 15 Fr	PR	UK	None	17
8	69	M	1	Low1	PE	5	50 Gy in 25 Fr	PR	UK	2 PE	20

¹Mixed pathology of small cell oesophageal cancer and adenocarcinoma.

²New primary with adenocarcinoma, patient had palliative chemotherapy. CE: Cisplatin and etoposide; CR: Complete response; CT: Chemotherapy; Fr: Fractions; M: Male; Mid: Middle; PE: Carboplatin and etoposide; Low: Lower; PS: Performance status; PR: Partial response; RT: Radiotherapy; Top: Topotecan; UK: Unknown; 2^nd Line CT: Second line chemotherapy.